ReviewCureus2026
Peri-Extubation Dexamethasone to Prevent Post-extubation Airway Obstruction in Critically Ill Children: A Systematic Review of Randomized Trials Across Heterogeneous Populations, Regimens, and Outcomes.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peri-extubation dexamethasone is used to prevent post-extubation upper airway obstruction in critically ill children, but pediatric randomized trials differ substantially in population selection, dosing, timing, and outcome definitions. We systematically reviewed randomized controlled trials evaluating peri-extubation dexamethasone in mechanically ventilated children. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to June 22, 2026. Nine trials randomized 1,063 children, with 949 included in reported analyses. Because comparator architecture, dexamethasone exposure, extubation context, outcome constructs, and follow-up windows were not clinically comparable, findings were synthesized narratively rather than pooled. Among placebo-controlled trials with interpretable pairwise binary airway outcomes, no trial provided statistically significant evidence of a reduction in the principal airway obstruction outcome. A 24-hour versus 6-hour regimen comparison reported less clinically significant airway obstruction with the 24-hour regimen, but the groups also differed in pre-extubation dose count and cumulative exposure, preventing attribution to timing alone. A low-dose versus high-dose trial did not establish non-inferiority of the lower-dose regimen. Reintubation outcomes showed no consistent treatment effect and were limited by imprecision and variable attribution. Adverse event ascertainment was limited. Seven trials raised some concerns, and two were at high overall risk of bias. Current randomized evidence does not define a single optimal peri-extubation dexamethasone regimen. Standardized eligibility criteria, explicit reporting of actual pre-extubation exposure, consistent airway outcome definitions, and prospective attribution of reintubation are needed before an optimal prophylactic strategy can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.